Clinical Trial: A Prospective, Single-Center, Phase II Clinical Study of Furmonertinib in Adjuvant Postoperative Treatment for Stage ⅠA Non-Small Cell Lung Cancer with High-Risk Factors and Positive EGFR Mutation (China)

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Single-Center, Phase II Clinical Study of Furmonertinib in Adjuvant Postoperative Treatment for Stage ⅠA Non-Small Cell Lung Cancer with High-Risk Factors and Positive EGFR Mutation'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133186

Registration Time: 2026/09/22

Type: Interventional study

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342807

Published by HT Digital Content Services with permission from Health Daily Digest....